Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial

医学 曲妥珠单抗 胃食管交界处 内科学 胃腺癌 多中心研究 肿瘤科 人表皮生长因子受体2 腺癌 胃肠病学 癌症 随机对照试验 乳腺癌
作者
Zhi Peng,Ping Chen,Jin Wei LU,Yiye Wan,Yulong Zheng,Feng Ye,Jianwei Yang,Ying Liu,Hongming Pan,Meili Sun,Qingxia Fan,Ying Yuan,Kai Chen,Zhuoer Sun,Han Tian,Xia Ye,Lin Shen
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:87: 103404-103404 被引量:16
标识
DOI:10.1016/j.eclinm.2025.103404
摘要

Background: Trastuzumab deruxtecan (T-DXd; 6·4 mg/kg) is approved for metastatic human epidermal growth factor receptor 2 (HER2)-positive (HER2+) gastric or gastroesophageal junction (GEJ) adenocarcinoma after a trastuzumab-based regimen. We report the final analysis of DESTINY-Gastric06, evaluating T-DXd in pretreated patients from China with advanced HER2+ gastric cancers (GC). Methods: The single-arm, multicenter, phase 2 DESTINY-Gastric06 trial (NCT04989816) enrolled patients from China with HER2+ (immunohistochemistry [IHC] 3+ or IHC 2+; locally documented) advanced gastric or GEJ adenocarcinoma with two or more prior treatments. Patients received T-DXd 6·4 mg/kg intravenous infusion every 3 weeks. The primary endpoint was confirmed objective response rate in HER2+ (IHC 3+ or IHC 2+/in situ hybridization-positive) tumors (full analysis set) by independent central review. Secondary endpoints included investigator-assessed confirmed objective response rate, progression-free survival by independent central review, overall survival, and safety. Findings: Of 126 patients screened between August 20, 2021, and December 7, 2022, 95 were enrolled (intent-to-treat; 73 patients had centrally confirmed HER2+ tumors). Median follow up was 10·2 months. Among the 73 patients, confirmed objective response rate (95% confidence interval) by independent central review was 28·8% (18·8-40·6%) and by investigator assessment was 37·0% (26·0-49·1%). Median progression-free survival by independent central review was 5·7 months. Median overall survival was 11·1 months. The most common Grade 1-2 adverse event was white blood cell count decreased (53·7%; 51/95). Interpretation: Consistent with other GC trials, T-DXd showed durable benefit, with no new safety signals, in pretreated patients from China with HER2+ advanced GC; data support T-DXd as a third- or later-line therapeutic option in this population. Funding: AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
荼蘼发布了新的文献求助10
1秒前
沉静忘幽发布了新的文献求助10
1秒前
852的应助被天穹雨采纳,获得10
1秒前
Orange的应助被老年学术废物采纳,获得10
2秒前
4秒前
舒适忆曼完成签到,获得积分10
4秒前
4秒前
lZzz发布了新的文献求助10
5秒前
5秒前
孤独盼望完成签到,获得积分10
5秒前
7秒前
soufle完成签到,获得积分10
8秒前
8秒前
DW的应助被捏鱼采纳,获得10
9秒前
搞怪的芾完成签到,获得积分10
9秒前
9秒前
Richardisme完成签到,获得积分10
9秒前
LIU发布了新的文献求助10
10秒前
荼蘼发布了新的文献求助10
10秒前
11秒前
11秒前
共享精神的应助被自觉的以寒采纳,获得10
12秒前
ppsy完成签到,获得积分10
12秒前
lll发布了新的文献求助10
12秒前
12秒前
tutu发布了新的文献求助10
12秒前
ket的应助被chen采纳,获得10
12秒前
甜甜的满天完成签到,获得积分10
13秒前
小二郎的应助被W1ndyKnight采纳,获得10
13秒前
13秒前
思源的应助被AA采纳,获得10
14秒前
XXX完成签到 ,获得积分10
15秒前
萍萍完成签到 ,获得积分10
15秒前
溺水小刀发布了新的文献求助10
16秒前
100发布了新的文献求助10
16秒前
nini发布了新的文献求助10
16秒前
syvshc的应助被小燕尾条采纳,获得10
16秒前
Yes完成签到,获得积分10
17秒前
李健的应助被浮晓采纳,获得10
17秒前
Eli发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241